IOVANCE BIOTHERAPEUTICS INC (IOVA) Fundamental Analysis & Valuation

NASDAQ:IOVA • US4622601007

Current stock price

3.63 USD
-0.06 (-1.63%)
At close:
3.64 USD
+0.01 (+0.28%)
After Hours:

This IOVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IOVA Profitability Analysis

1.1 Basic Checks

  • In the past year IOVA has reported negative net income.
  • In the past year IOVA has reported a negative cash flow from operations.
  • IOVA had negative earnings in each of the past 5 years.
  • In the past 5 years IOVA always reported negative operating cash flow.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • The Return On Assets of IOVA (-42.82%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -55.97%, IOVA is in the better half of the industry, outperforming 61.66% of the companies in the same industry.
Industry RankSector Rank
ROA -42.82%
ROE -55.97%
ROIC N/A
ROA(3y)-46.87%
ROA(5y)-48.85%
ROE(3y)-61.44%
ROE(5y)-63.72%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • The Gross Margin of IOVA (28.66%) is better than 72.25% of its industry peers.
  • The Profit Margin and Operating Margin are not available for IOVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. IOVA Health Analysis

2.1 Basic Checks

  • IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IOVA has been increased compared to 1 year ago.
  • The number of shares outstanding for IOVA has been increased compared to 5 years ago.
  • IOVA has a better debt/assets ratio than last year.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • IOVA has an Altman-Z score of -0.76. This is a bad value and indicates that IOVA is not financially healthy and even has some risk of bankruptcy.
  • IOVA's Altman-Z score of -0.76 is in line compared to the rest of the industry. IOVA outperforms 56.84% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that IOVA is not too dependend on debt financing.
  • IOVA has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: IOVA outperforms 51.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.76
ROIC/WACCN/A
WACC9.28%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.20 indicates that IOVA has no problem at all paying its short term obligations.
  • The Current ratio of IOVA (3.20) is worse than 61.85% of its industry peers.
  • IOVA has a Quick Ratio of 2.83. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.83, IOVA is doing worse than 64.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 2.83
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. IOVA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 13.85% over the past year.
  • IOVA shows a strong growth in Revenue. In the last year, the Revenue has grown by 60.60%.
EPS 1Y (TTM)13.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
Revenue 1Y (TTM)60.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%

3.2 Future

  • Based on estimates for the next years, IOVA will show a very strong growth in Earnings Per Share. The EPS will grow by 20.21% on average per year.
  • Based on estimates for the next years, IOVA will show a very strong growth in Revenue. The Revenue will grow by 27.64% on average per year.
EPS Next Y54.18%
EPS Next 2Y34.08%
EPS Next 3Y27.13%
EPS Next 5Y20.21%
Revenue Next Year52.08%
Revenue Next 2Y44.63%
Revenue Next 3Y41.58%
Revenue Next 5Y27.64%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. IOVA Valuation Analysis

4.1 Price/Earnings Ratio

  • IOVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IOVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IOVA's earnings are expected to grow with 27.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.08%
EPS Next 3Y27.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IOVA Dividend Analysis

5.1 Amount

  • IOVA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IOVA Fundamentals: All Metrics, Ratios and Statistics

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (3/23/2026, 8:00:03 PM)

After market: 3.64 +0.01 (+0.28%)

3.63

-0.06 (-1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners64.07%
Inst Owner Change16.6%
Ins Owners0.33%
Ins Owner Change13.44%
Market Cap1.50B
Revenue(TTM)263.50M
Net Income(TTM)-390.98M
Analysts78.82
Price Target9.29 (155.92%)
Short Float %34.48%
Short Ratio8.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.11%
Min EPS beat(2)-2.78%
Max EPS beat(2)5%
EPS beat(4)1
Avg EPS beat(4)-14.73%
Min EPS beat(4)-47.45%
Max EPS beat(4)5%
EPS beat(8)5
Avg EPS beat(8)-4.74%
EPS beat(12)8
Avg EPS beat(12)3.08%
EPS beat(16)11
Avg EPS beat(16)3.15%
Revenue beat(2)1
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-8.66%
Max Revenue beat(2)5.4%
Revenue beat(4)1
Avg Revenue beat(4)-14.96%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)5.4%
Revenue beat(8)3
Avg Revenue beat(8)-11.95%
Revenue beat(12)3
Avg Revenue beat(12)-37.01%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.11%
PT rev (3m)10.44%
EPS NQ rev (1m)11.26%
EPS NQ rev (3m)11.26%
EPS NY rev (1m)13.54%
EPS NY rev (3m)14.31%
Revenue NQ rev (1m)1.6%
Revenue NQ rev (3m)1.6%
Revenue NY rev (1m)-4.08%
Revenue NY rev (3m)-5.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.68
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 3.57
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0.64
BVpS1.7
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.82%
ROE -55.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.66%
FCFM N/A
ROA(3y)-46.87%
ROA(5y)-48.85%
ROE(3y)-61.44%
ROE(5y)-63.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 94.15%
Cap/Sales 12.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.2
Quick Ratio 2.83
Altman-Z -0.76
F-Score4
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)77.2%
Cap/Depr(5y)331.82%
Cap/Sales(3y)631.42%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
EPS Next Y54.18%
EPS Next 2Y34.08%
EPS Next 3Y27.13%
EPS Next 5Y20.21%
Revenue 1Y (TTM)60.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%
Revenue Next Year52.08%
Revenue Next 2Y44.63%
Revenue Next 3Y41.58%
Revenue Next 5Y27.64%
EBIT growth 1Y-2.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.33%
OCF growth 3YN/A
OCF growth 5YN/A

IOVANCE BIOTHERAPEUTICS INC / IOVA Fundamental Analysis FAQ

What is the fundamental rating for IOVA stock?

ChartMill assigns a fundamental rating of 2 / 10 to IOVA.


What is the valuation status for IOVA stock?

ChartMill assigns a valuation rating of 1 / 10 to IOVANCE BIOTHERAPEUTICS INC (IOVA). This can be considered as Overvalued.


How profitable is IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?

IOVANCE BIOTHERAPEUTICS INC (IOVA) has a profitability rating of 1 / 10.


Can you provide the financial health for IOVA stock?

The financial health rating of IOVANCE BIOTHERAPEUTICS INC (IOVA) is 3 / 10.